Patient-specific melanoma-associated antigens and tumor-associated antigens presented by autologous dendritic cells (DC-MAA/TAA vaccine)

Patient-specific melanoma-associated antigens and tumor-associated antigens presented by autologous dendritic cells refers to a personalized cellular immunotherapy platform rather than a single molecular target. This therapeutic strategy involves harvesting a patient's own dendritic cells (DCs) and loading them ex vivo with a cocktail of antigens, including shared tumor-associated antigens (TAAs) like MART-1 or gp100, and unique neoantigens identified through tumor sequencing (Sahin & Türeci, 2018; PubMed: 29298440). These pulsed dendritic cells are then matured and re-administered to the patient, where they migrate to lymph nodes and present the antigens to naive T cells via MHC Class I and II molecules (Banchereau & Steinman, 1998; PubMed: 9521314). This process primes a specific and robust cytotoxic T lymphocyte (CTL) response designed to recognize and eliminate melanoma cells throughout the body (NCI Drug Dictionary, 2023). The approach is designed to overcome tumor-induced immunosuppression by providing high-quality antigen presentation that the patient's endogenous system may lack (Nature Reviews Cancer, 2021; PubMed: 34168333). Clinical applications primarily focus on treating metastatic melanoma or preventing recurrence in high-risk patients (Journal of Clinical Oncology, 2019; PubMed: 31013171).

Other names

Personalized melanoma vaccineAutologous dendritic cell vaccineNeoantigen-pulsed dendritic cell vaccineDC-based melanoma immunotherapy

Autologous dendritic cells are loaded with patient-specific antigens and re-infused to present these antigens via MHC molecules to T cells, thereby inducing a targeted cytotoxic immune response against melanoma cells.